1	Responsiveness to pulmonary rehabilitation in people with COPD is associated with			
2	changes in microbiota			
3	Sara Melo-Dias ^{1,2,3} , Msc, Miguel Cabral ^{1,3} , Bsc, Andreia Furtado ^{1,3} , Msc, Sara Souto-Miranda ^{2,4} , Msc, Maria Aurora			
4	Mendes ^{3,5} , MD, João Cravo ⁵ , MD, Catarina R. Almeida ^{1,3} , PhD, Alda Marques ^{2,3} , PhD [‡] and Ana Sousa ^{1,3} , PhD [‡]			
5 6 7 8 9 10 11	Affiliations: ¹ Department of Medical Sciences, University of Aveiro, Aveiro, Portugal; ² Lab3R – Respiratory Research and Rehabilitation Laboratory, School of Health Sciences (ESSUA), University of Aveiro, Aveiro, Portugal; ³ Institute of Biomedicine (iBiMED), University of Aveiro, Aveiro, Portugal; ⁴ Department of Respiratory Medicine, Maastricht University Medical Centre, NUTRIM School of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.; ⁵ Department of Pulmonology of the Hospital Center of Baixo Vouga [‡] These authors contributed equally to this study.			
12	Correspondence: Ana Sousa, Department of Medical Sciences, Institute of Biomedicine, University of Aveiro,			
13	<u>3810-193 Aveiro, Portugal (amsousa@ua.pt)</u>			
14	Abstract			
15	Rationale: Pulmonary Rehabilitation (PR) is one of the most cost-effective therapies for			
16	chronic obstructive pulmonary disease (COPD) management. There are, however, people who			
17	do not respond to PR and reasons for non-response are mostly unknown. PR is likely to change			
18	the airway microbiota and this could play a role in its responsiveness.			
19	Objectives: In this study we have explored the association between PR effectiveness and			
20	specific alterations in oral microbiota and inflammation.			
21	Methods: A prospective longitudinal study was conducted. Data on exercise capacity,			
22	dyspnoea, impact of disease and 418 saliva samples were collected from 76 patients, half of			
23	whom participated in a 12-weeks PR programme. Responders and non-responders to PR			
24	(dyspnoea, exercise-capacity and impact of disease) were defined based on minimal clinically			
25	important differences.			
26	Measurements and Main Results: Changes in microbiota, including Prevotella			
27	neterthiogeniitceand streptocolocus we bee been been propriper in the outer hope previously fixed been been been been been a constructed of the previous of th			

28	depleted in severe COPD, increased during the first month of PR in responders. This increase
29	was negatively correlated with Streptoccus and Lautropia, known to be enriched in severe
30	cases of COPD. Simultaneously, an anti-inflammatory commensal of the respiratory tract,
31	Rothia, correlated strongly and negatively with several pro-inflammatory markers, whose
32	levels were generally boosted by PR.
33	Conversely, in non-responders, the observed decline in <i>Prevotella</i> correlated negatively with
34	Streptococcus and Lautropia whose fluctuations co-occurred with several pro-inflammatory
35	markers.
36	Conclusions: PR is associated with changes in oral microbiota. Consistent patterns of
37	bacteria/pro-inflammatory markers among responders and non-responders were unraveled,
38	which may contribute to explain the success of PR.
39	Key words: oral microbiota; inflammation; COPD; pulmonary rehabilitation; responsiveness

41 Introduction

Chronic obstructive pulmonary disease (COPD) is heterogenous and complex and therefore, difficult to treat and manage. Pulmonary rehabilitation (PR) is a grade A non-pharmacological therapy and one of the most cost-effective approaches for the management of COPD (1). Compared to pharmacological treatment, PR is three to five times more effective in improving exercise capacity, dyspnoea, and quality of life (2). Response to PR is however multidimensional and heterogeneous, which means that for the same outcome patients are not equally responsive (3). Reasons behind non-response are mostly unknown (3, 4).

An association between the airway microbiota, including the oral microbiota (5), and disease 49 50 severity has been extensively established in people with COPD (6–8). However, the impact of PR on the airway microbiota has not yet been investigated, mainly because of the difficulty in 51 52 collecting airway samples, such as sputum and bronchoalveolar lavage (BAL), routinely. 53 Considering that only around 30% of people with COPD have productive cough (1), induce sputum production becomes the only viable alternative. Unfortunately, this is challenging to 54 55 collect outside the hospital context and requires both specialized personnel and equipment. The acquisition of BAL samples is even more challenging, as it is limited to hospital centres 56 and bronchoscopy in patients with COPD carries a significantly higher risk of complications 57 58 such as pneumonia, respiratory failure and desaturation compared with those with normal lung function (9). In this scenario, saliva emerges as a viable non-invasive alternative to 59 sampling the airway microbiota, which collection is simple and can be performed in different 60 settings, namely at-home. Moreover, the oral and lower microbiotas are highly correlated 61 62 (10), given the topological continuity between the niches, implying oral bacteria as the major colonizers of the lungs through aspiration (10–12). 63

64	An additional reason to choose saliva to evaluate the effect of PR in the airway microbiota, is
65	the role of oral bacteria in nitrate metabolism. Exercise training, one of the main components
66	of PR, stimulates the synthesis of nitric oxide by the human body, which is a key regulator of
67	skeletal muscle blood flow, contractility, and mitochondrial function (13). Oral microbiota has
68	been strongly implicated in exercise performance, mainly due to its essential role in nitrate-
69	nitrite-nitric oxide pathway (14, 15), with recent studies showing nitrate oral supplementation
70	to enhance PR effectiveness (16). The oral microbiota although acknowledged as essential for
71	this positive effect, was never studied.
72	On the other hand, microbiota modifications are frequently connected with an inflammatory
73	response, which is well known to be modulated by exercise (17) and affected by PR, although
74	with inconsistent results (18–20).
75	Here, we have explored the association between PR and changes in oral microbiota and
76	inflammatory markers of people with COPD to propose that PR effectiveness could be related,
77	at least partially, with bacterial-driven immune regulation.
78	Some of the results of this study have been previously reported in the form of abstracts (21–

79 23).

81 Methods

A prospective longitudinal cohort study was conducted. Ethical approvals were obtained from Administração Regional de Saúde Centro (64/2016), Centro Hospitalar do Baixo Vouga (including Estarreja's Hospital; 08-03-17) and Agrupamento dos Centros de Saúde do Baixo Vouga. Written informed consent was obtained from all participants.

86 The study was reported following the "Strengthening the Reporting of Observational Studies 87 in Epidemiology" statement (24). Participants were identified and referenced by clinicians who briefly explained the purposes of the study. Participants were eligible if diagnosed with 88 COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria 89 (25) and stable with no acute exacerbations in the month prior to enrolment. Exclusion criteria 90 were presence of severe cardiac, musculoskeletal, or neuromuscular diseases, signs of 91 92 cognitive impairment, active neoplasia or immune diseases, that could hinder their 93 participation in PR.

The opportunity to be integrated in the PR programme was offered to all participants. Those who did not accept to participate in the intervention but agreed with being monitored during the 5-month period were included in the control group. The intervention group (n=38) undertook a 12-week community-based PR program, whereas the control group (n=38) did not.

99 Sociodemographic (age, sex), anthropometric (height and weight) and general clinical 100 (smoking habits; medication, long-term oxygen use; number of acute exacerbations and 101 hospitalizations in the past year and comorbidities - Charlson Comorbidity Index) data were 102 collected with a structured questionnaire. Lung function was assessed with spirometry as 103 recommended (26). Exercise capacity was assessed with the six-minute walk test (6MWT), a 104 self-paced test of walking capacity (27). Impact of the disease was assessed with the COPD 105 assessment test (CAT), a 8-item questionnaire, each assessed with a 6-point Likert scale (28,

106 29). Dyspnoea at rest was assessed with the modified Borg Scale (mBorg), a 10-item scale.
107 Clinical data and saliva samples were collected with a structured protocol adapted from the
108 team published work (30).

109 Response/non-response to PR was determined based on published minimal clinical 110 importance differences (MCIDs), i.e., -1 point for mBorg (31); 25m for 6MWT (32) and -2 111 points for CAT (33).

Deep sequencing of the V4 hypervariable region of 16S rRNA gene (F515/R806 primer pair) 112 113 was performed for all samples. The bead assay LEGENDplex[™] Human Inflammation Panel 1 (13-plex) (BioLegend, San Diego, CA, USA) was used to quantify inflammatory markers (IL-1β, 114 IFN-α2, IFN-γ, TNF-α, MCP-1, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23, and IL-33) in both 115 116 groups in three timepoints, M0, M1 and M3. QIIME2 2020.8 (34, 35) was used to perform microbiota analyses. All statistical analyses were performed in GraphPad Prism 8 (36) and R 117 118 software v 3.6.1 (37). Longitudinal models (*Ime4* package (38)) and repeated-measures correlations (rmcorr package (39)) were performed in R software v 3.6.1 (37). The full 119 description of the methodology used, including all steps of data collection, processing, and 120 121 data analyses, are available in Supplementary file 1.

122

123

124 Results

125 Cohort characterisation

Seventy-six individuals with COPD were included in this study, 38 (29 male, 72±9y, BMI:
26±4kg/m², FEV₁pp 49.2±16 % predicted, GOLD A-8, B-20, C-0, D-10) in the intervention group
and the remaining 38 patients (31 male, 70±8y, BMI: 26.4±4.8kg/m², FEV₁pp 52.3±19.8 %

- 129 predicted, GOLD A-17, B-12, C-1, D-8) in the control group. Table 1 summarizes the baseline
- 130 characteristics of the two groups. No significant differences were found between groups (see
- 131 Table 1), and therefore, no adjustment for confounding factors was performed.
- 132 Oral microbiota was similar between groups, being composed by two major phyla, Firmicutes
- 133 (~43%) and Bacteroidetes (~24%), followed by Proteobacteria, Fusobacteria, Actinobacteria
- and ten low abundant phyla (<2%) (Supplementary figure 1).
- 135 Changes in oral microbiota and inflammatory response are associated with PR

We followed the temporal dynamics of beta-diversity (global rate of change (grc) of Weighted-Unifrac distance) in patients for a period of five months, including the 12 weeks of PR, to understand the impact of PR in microbiota composition. As a control for steady-state microbiota fluctuations, an independent cohort of patients who did not undergo PR, was surveyed for an equivalent amount of time.

The dynamics of microbiota composition was significantly different between patients undergoing PR and controls (Figure 1A) (Imer on Weighted-Unifrac distance (grc), Group:Timepoint, F= 7.58, p<0.001).

Principal coordinate analysis of pairwise distances (Weighted Unifrac) between groups in each timepoint showed significant differences in microbiota composition between groups upon one month of PR (Figure 1B) (PERMANOVA, F=2.3, *p*=0.038). The top four amplicon sequence variants (ASVs) responsible for individual's separation after the first month of PR were identified as *Veillonella*, *Prevotella melaninogenica*, *Haemophilus parainfluenzae* and *Streptococcus*.

Regarding microbiota diversity within individuals (alpha diversity), no significant changes were
observed upon PR (Figure 1C) (Wilcoxon test on phylogenetic diversity: W= -85. p=0.48;
Wilcoxon test on Shannon diversity: W= -1. p>0.99).

Next, we compared the microbiota composition of the intervention group at baseline with that at M1, M2 and M3, to identify which taxa could have been affected by PR. PERMANOVA (M0vsM1: F=0.6, p_{adjust} >0.99; M0vsM2: F=1.3, p_{adjust} >0.99; M0vsM3: F=1.2, p_{adjust} >0.99; M0vsM4: F=1, p_{adjust} >0.99; M0vsM5: F=1.4, p_{adjust} =>0.99), ANCOM and LEfSe detected no significant differences between pre- and post-PR microbiota composition. This is compatible with the inherent correlation among the groups (composed by the same individuals) being stronger than differences introduced by PR.

To overcome this limitation, given the longitudinal design of the experiment, we next tested 160 for differences in taxa dynamics between the intervention and control group. This was 161 162 performed using linear mixed-effect models. The temporal dynamics of the phylum 163 Fusobacteria (Imer, Group:Time-point, F= 5.9, p=0.02) and several oral genera, such as Fusobacterium, Streptococcus, Dialister and Selenomonas were observed to be associated 164 with PR (Table 2). Target testing for the top four ASVs distinguishing patients on M1 was also 165 performed. Remarkably, significant alterations in the relative abundances of Prevotella 166 melaninogenica and Streptococcus, two ASVs previously associated with disease severity in 167 168 people with COPD (5), were also found (Imer, *P. melaninogenica:* Group:Time-point, F= 4.34, p=0.04; Imer, *Streprococcus:* Group:Time-point, F= 4.96, p=0.03). 169

170 Considering that changes in microbiota are expected to be related with the inflammatory 171 response, we further quantified a panel of 13 cytokines in three time points: M0, M1 and M3 172 in both intervention and control groups (Figure 2 and Supplementary figure 2). Significant

173 changes in the inflammatory profile of patients undergoing PR were observed (Figure 2). 174 Specifically, upon one month of PR (M1) significant increases in the amounts of IL-10 and IL-18 were observed (Wilcoxon signed-rank: IL-10, W=163 p_{adiust} =0.038; IL-18, W=165 175 p_{adjust} =0.035). No significant changes were observed in the same period in control group. After 176 three months of PR (M3), TNF- α , IL-1 β , IL-18, IL-10 and IL-6 were also significantly higher than 177 178 at baseline (M0) (Wilcoxon signed-rank: IL-1 β , W=205 p_{adjust} =0.016; TNF- α , W=251 179 p_{adjust}=0.002; IL-10, W=263 p_{adjust}=0.0008; IL-6, W=189 p_{adjust}=0.03; IL-18, W=233 p_{adjust}=0.004). 180 IL-10 and IL-6 also increased in the control group over the same time interval (Wilcoxon signed-rank: IL-10, W=225 padjust=0.018; IL-6, W=224 padjust=0.019), suggesting that these 181 cytokines may be less stable. 182

183 Regarding comparisons between the groups, shifts in IL-10 and IL-18 were significantly higher 184 after 1 month of PR than the equivalent shifts in the control group (Mann-Whitney U-test, IL-185 10, U=180 p=0.043; IL-18, U=173 p=0.03). Over 3 months of PR, TNF- α , IL-18 and IL-10 had 186 significantly higher shifts in the intervention than in the control group (Mann-Whitney U-test, 187 TNF- α , U=246 p=0.04; IL-10, U=196 p=0.0004; IL-18, U=249 p=0.046). No additional significant 188 differences were found in both groups (Supplementary figure 2).

189 Interestingly, the variance associated with cytokine shifts over time was generally higher in 190 the intervention than in the control group (Supplementary table 2). This is compatible with PR 191 generally influencing cytokine levels.

Oral microbiota and inflammatory response vary differentially among responders and non-responders during PR

PR improved all outcomes significantly (Wilcoxon test, p < 0.05), except for BMI (W=-114, p=0.31) and mBorg (W=37, p=0.5) (Supplementary table 3). Mean improvements only exceeded the MCID for exercise capacity (6MWT, mean-diff: 45.43; Cohen's d=0.34)

(Supplementary table 2). Supplementary figure 3 represents the overlap between responders
(R) and non-responders (NR) to PR in exercise capacity (6MWT), impact of disease (CAT) and
dyspnoea (mBorg). From 38 patients, 9 responded in dyspnoea (NR: n=29), 24 responded in
exercise capacity (NR: n=14) and 24 responded in the impact of disease (NR: n=14). Six patients
responded simultaneously to all three domains and six failed to respond to any domain.

We analysed differences in microbiota composition among R and NR at M0 to query for a 202 203 possible relationship between microbiota composition before PR and its effectiveness (Figure 204 3A). Principal coordinate analysis of pairwise distances (Weighted-Unifrac) showed significant 205 differences between R and NR to dyspnoea (PERMANOVA p = 0.04) and captured 66% of total 206 diversity (Figure 3B). Furthermore, the ASV responsible for the biggest separation between individuals in this analysis, was P. melaninogenica, whose frequency was below average in 207 208 75% of R. In accordance, the differential abundance analysis (LEfSe) showed that Prevotella 209 (Figure 3C) was significantly enriched in NR to dyspnoea, with an effect-size of 9. No significant differences were observed for the other domains. 210

211 Next, we used linear mixed effect models to compare the microbiota temporal dynamics between R and NR. Despite being differentially represented in R and NR (to dyspnoea) before 212 PR, the frequency trajectory of *P. melaninogenica* was not significantly different among the 213 214 two sets of patients during the intervention. Instead, several other taxa were found to have 215 significantly different trajectories between the groups (Table 3 and Supplementary figure 4). 216 Regarding the exercise capacity, the frequency trajectory of Lautropia (family Burkholderiaceae) was significantly different between R and NR (Imer, Group:Time-point, F= 217 2.9, p=0.02), reaching higher values in NR by the end of PR (Supplementary figure 3). The 218

219 dynamics of *P. melaninogenica* was distinct among R and NR (Imer, Group:Time-point, F= 2.6,

p=0.03) to impact of disease (Supplementary figure 4).

221 We compared the salivary levels of cytokines present in R and NR to question whether responsiveness to PR was related with the inflammatory response. Distinct patterns of 222 223 inflammatory response were observed between R and NR, in all domains (Supplementary figure 5). Significant shifts during PR were always towards values higher than the baseline and 224 occurred mainly in NR patients. Specifically, after PR, levels of TNF α , IL-1 β , IL-18 and IL-10 225 226 were higher in NR of all domains, whereas only TNF- α and IL-10 showed significant changes in 227 R patients (please see Supplementary figure 5 for details on the statistical tests results). 228 Interestingly, the variance in cytokine shifts after PR was also mostly higher in NR than in R 229 (Supplementary tables 4–6).

230 PR effectiveness is related with specific bacteria-inflammation correlation signatures

Independent analyses revealed an association between PR effectiveness and either changes in oral microbiota or inflammatory markers. We explored the patterns of longitudinal correlation between the two to understand in what extent PR effectiveness is linked with specific bacteria-inflammation associations. Figure 4 represents the network of significant correlations between inflammatory markers and bacterial genera inferred for the three domains. Remarkably, R and NR presented distinct patterns of bacteria-cytokine correlation (Figure 4).

In all groups of NR, *Lautropia* showed a strong positive correlation with several proinflammatory cytokines, being the strongest with TNF- α in NR to exercise capacity (rmcorr = 0.65, *p*=0.002) and impact of the disease (rmcorr = 0.63, *p*=0.002). Conversely, *Rothia* presented a negative correlation with several pro-inflammatory markers in all groups of R,

with the strongest correlation with TNF- α (rmcorr = -0.73, *p*=0.007). Furthermore, *Gemellaceae*, was also negatively correlated with several inflammatory markers (strongest with IL-8, rmcorr = -0.69, *p*<0.0001) in R to exercise capacity and impact of the disease. Strikingly, except for a positive correlation between *Haemophilus* and IFN- α 2 in R to impact of the disease (rmcorr = 0.43, *p*=0.03), all significant correlations with Proteobacteria were found in NR.

248 We then performed a longitudinal correlation analysis between bacterial frequencies to gain 249 further insight on bacterial interactions that might be related with PR responsiveness but are 250 not necessarily linked with the immune response (Figure 5). In an effort to be conservative, 251 since compositional data are intrinsically correlated, we chose a subset of taxa for this analysis. We included the major hubs found in the correlation between bacteria and 252 253 inflammatory markers (Lautropia, Rothia, Gemellaceae and Kingella), plus five other oral taxa 254 previously associated (5) with severity (Prevotella, P. melaninogenica, Streptococcus, Streptococcus sp., Haemophilus and Porphyromonas). 255

256 In this analysis, *Prevotella*, whose frequency drops during PR in all NR (Supplementary figure 6 A-C), was negatively correlated with *Haemophilus* (rmcorr = -0.46, *p*=0.005), *Streptococcus* 257 (rmcorr = -0.37, p=0.03) and Lautropia (rmcorr = -0.41, p=0.01) in NR to dyspnoea and with 258 Haemophilus (rmcorr = -0.73, p=0.0004) in NR to exercise capacity. Conversely, during the first 259 260 month of PR, the frequency of P. melaninogenica increased in all R (Supplementary figure 6A-261 C) and was negatively correlated with *Kingella* (R to dyspnoea, rmcorr = -0.59, p=0.04), Lautropia (R to exercise capacity, rmcorr = -0.52, p=0.004; R to impact of the disease, rmcorr 262 263 = -0.43, p=0.03) and Streptococcus (R to impact of the disease, rmcorr = -0.41, p=0.04).

Gemellaceae and Rothia were strongly positively correlated in all R (strongest in dyspnoea,
 rmcorr = 0.9, p<0.0001).

266

267

268 Discussion

269 We show, for the first time, that oral microbiota changes with PR and that shifts in specific taxa appear to be strongly related with its effectiveness. By tracking two independent groups 270 271 of patients for almost half a year we were able to discriminate between steady-state 272 microbiota fluctuations and those possibly induced by PR. Contrary to the simple expectation that a well-established therapy should positively impact on patients' microbiota, a more 273 complex reality was unravelled. Overall, PR was not able to boost microbiota diversity within 274 patients, a hallmark of dysbiosis, causing only low magnitude changes in a few taxa, and 275 elicited the secretion of several pro-inflammatory cytokines. 276

However, when considering separately R and NR, taxa potentially related with responsiveness 277 278 emerges and a differential inflammatory response becomes apparent. Previously, we have observed that low frequency of *Prevotella*, and in particular *P. melaninogenica*, was associated 279 280 with a recent history of severe exacerbation (5). Here we observed that in the first month of PR Prevotella was boosted in R of all domains. We hypothesize that this boost could be directly 281 282 or indirectly related with the ability to respond. For example, by directly inducing the 283 reduction of lung epithelial cell permeability (by modulating expression of tight junction 284 proteins) (40), or indirectly by promoting lung innate immune responses, particularly against 285 Streptococcus pneumoniae (41) and Lautropia, to which it was negatively correlated.

In fact, it has been recently observed that *P. melaninogenica* is able to promote *S. pneumoniae* rapid clearance from the lung via TLR2 activation, recruitment of neutrophils and upregulation
 of TNFα and IL-10 (42). Interestingly, it was also observed that the aspiration of a mixture of 3
 species of human oral commensals in mice, including *P. melaninogenica*, decreased host's
 susceptibility to *S. pneumoniae* (41).

Supporting the hypothesis that, by counteracting *Lautropia*, *Prevotella* could be positively associated with PR effectiveness, is the observation that *Lautropia* is enriched in the oral microbiota of more severe cases of COPD (5) and co-occur with high levels of inflammatory markers in the eosinophilic COPD (43), an endotype that has been suggested to be predictive of worse outcome upon PR (44).

296 Conversely, in NR to dyspnoea and exercise capacity, the opposite scenario was observed, that 297 is, a clear decline in *Prevotella* upon PR, negatively correlated with *Haemophilus* (exercise 298 capacity) and with *Streptococcus* and *Lautropia* (dyspnoea). A pro-inflammatory role in COPD 299 has been repeatedly attributed to the first two taxa (45) which could likely contribute to the 300 lack of response to this therapy. Besides this, *Lautropia* positively correlated with several pro-301 inflammatory markers in all groups of NR.

Another striking observation, possibly related with the success of PR across the three domains, was the co-occurrence of *Rothia* and *Gemellacea* (in R) and its negative correlation with several pro-inflammatory markers during PR. *Rothia mucilaginosa* (the most abundant species of *Rothia* genus in our dataset) has been identified as an anti-inflammatory bacterium when present in the lungs (even in low abundance) of people with chronic respiratory diseases (46). This has been attributed to its ability to reduce the levels of several pro-inflammatory

308 cytokines and NF-kB activation in response to immune stimulation by pathogenic bacteria like
 309 *Pseudomonas aeruginosa* and *Staphylococcus aureus* (46).

Considering the impact of PR on individual species, this was significant on the longitudinal dynamics of two particular ASVs, *P. melaninogenica* and *Streptococcus*, previously suggested to be associated with COPD severity (5). Moreover, the longitudinal dynamics of *P. melaninogenica* was distinct among R and NR to impact of the disease, supporting its importance to PR effectiveness.

Besides its immunomodulatory properties, *P. melaninogenica* could have an additional role in PR effectiveness, since it belongs to the most prevalent genus of oral nitrate-reducing bacteria (47). These are essential for the nitrate nitric oxide pathway which is implicated in exercise performance and recovery (14, 15). Coherently, it has been shown that nitrate oral supplementation increased the beneficial effects of PR (16).

320 Some limitations of our study need to be acknowledged. First, the use of saliva for COPD 321 assessment is still exploratory. Although the microbiota of upper and lower airways is highly correlated, with oral bacteria being the major colonizers of the lungs through microaspiration 322 323 (10–12), more studies, besides Melo-Dias et al (5) validating its biological relevance in the context of COPD are needed. Additionally, despite longitudinal studies including PR being very 324 325 resource demanding, further works with similar design should be carried out, ideally including 326 multicentric trials with larger cohorts to assess the robustness of the findings. Second, 327 multiple confounders such as occurrence of exacerbations, treatment with inhaled-328 corticosteroids and/or antibiotics are present. Therefore, future studies should try to 329 disentangle its effects from the PR-induced microbiota modulation.

Overall, besides responsiveness to PR being multidimensional and heterogeneous, giving rise to a moderate overlap in individuals response across domains, PR-induced changes in microbiota revealed surprisingly consistent patterns among R and NR. Furthermore, our findings suggest that PR effectiveness could be associated with a controlled inflammatory response to exercise, *i.e.*, the inflammatory response to exercise occurs accompanied by efficient regulatory mechanisms. These mechanisms can be mediated by bacteria and could be tested *in vitro*.

- 337 Future studies should address the implications and stability of these findings, clarifying the
- role of oral microbiota both as a biomarker of PR responsiveness and as a therapeutic target.

339 Acknowledgements:

340 Author contributions:

S. Melo-Dias and A. Sousa had full access to all data in the study and take responsibility for the 341 integrity of the data and the accuracy of the data analysis. A. Marques was responsible for 342 343 ethical approval. A. Marques and A. Sousa were responsible for obtaining the funding, conceiving and designing the study. M. A. Mendes, J. Cravo and S. Souto-Miranda provided a 344 substantial contribution for clinical data acquisition. S. Melo-Dias A. Furtado conducted 345 sample processing, DNA extraction procedures and inflammatory markers quantification. S. 346 Melo-Dias, M. Cabral, A. Furtado, C. R. Almeida and A. Sousa conducted bioinformatics and 347 348 statistical analyses. S. Melo-Dias and A. Sousa drafted the manuscript. All authors critically revised the manuscript, ensured accuracy and integrity of the work and approved the final 349 350 version to be published.

351 Funding:

This study is integrated in "PRIME – Pulmonary Rehabilitation and microbiota in exacerbations 352 of COPD", "GENIAL - Genetic and Clinical markers of COPD trajectory", and "MicroAgeing -353 354 The role of microbiota in ageing", funded by Programa Operacional de Competitividade e Internacionalização - COMPETE, through Fundo Europeu de Desenvolvimento Regional -355 356 FEDER (POCI-010145-FEDER-028806 and POCI-01-0145-FEDER-007628), Fundação para a Ciência e Tecnologia - FCT (PTDC/DTP-PIC/2284/2014, PTDC/SAU-SER/28806/2017 and 357 PTDC/BIA-EVL/30212/2017) and under the project UIDB/04501/2020. S. Melo-Dias was 358 supported by Grant SFRH/BD/140908/2018 from FCT. A. Sousa was funded from national 359 funds through FCT – Fundação para a Ciência e a Tecnologia, I.P., under the Scientific 360 Employment Stimulus - Institutional Call - reference CEECINST/00026/2018. 361

362 Availability of data and materials:

- 363 The dataset supporting the conclusions of this article is included within the article (and its
- additional file(s)). Furthermore, raw sequencing data was deposited in National Centre for
- Biotechnology Information's (NCBI) Sequence Read Archive (SRA) (BioProject PRJNA872131).
- 366 Scripts for data analyses are provided in supplementary file 1.
- 367 Ethics approval and consent to participate:
- 368 A cross-sectional study was conducted. Ethical approvals were obtained from Administração
- Regional de Saúde Centro (64/2016) and from Centro Hospitalar do Baixo Vouga (08-03-17).
- 370 Written informed consent was obtained from all participants.
- 371 Consent for publication:
- 372 Not applicable.
- 373 Competing interests:
- 374 S. Melo-Dias has nothing to disclose. M. Cabral has nothing to disclose. A. Furtado has nothing
- to disclose. S. Souto-Miranda has nothing to disclose. M. A. Mendes has nothing to disclose.
- J. Cravo has nothing to disclose. C. R. Almeida has nothing to disclose. A. Marques has nothing
- to disclose. A. Sousa has nothing to disclose.
- 378 Acknowledgements:
- We are grateful to all people with COPD who accepted to participate in this study and to the team of Respiratory Research and Rehabilitation Laboratory, School of Health Sciences (Lab3R-ESSUA) for their support.

382 References

383 1. 2022 GOLD Reports. Global Initiative for Chronic Obstructive Lung Disease - GOLD at

384 <https://goldcopd.org/2022-gold-reports-2/>.

- 2. Casaburi R. Pulmonary Rehabilitation: Where We've Succeeded and Where We've Failed. COPD:
- *Journal of Chronic Obstructive Pulmonary Disease* 2018;15:219–222.
- 387 3. Augustin IML, Franssen FME, Houben-Wilke S, Janssen DJA, Gaffron S, Pennings H-J, Smeenk
- 388 FWJM, Pieters WR, Hoogerwerf A, Michels A-J, Merode F van, Wouters EFM, Spruit MA.
- 389 Multidimensional outcome assessment of pulmonary rehabilitation in traits-based clusters of
- 390 COPD patients. *PLOS ONE* 2022;17:e0263657.
- 391 4. Spruit MA, Augustin IML, Vanfleteren LE, Janssen DJA, Gaffron S, Pennings H-J, Smeenk F, Pieters
- 392 W, van den Bergh JJAM, Michels A-J, Groenen MTJ, Rutten EPA, Wouters EFM, Franssen FME,
- 393 CIRO+ Rehabilitation Network. Differential response to pulmonary rehabilitation in COPD:
- 394 multidimensional profiling. *Eur Respir J* 2015;46:1625–1635.
- 395 5. Melo-Dias S, Valente C, Andrade L, Marques A, Sousa A. Saliva as a non-invasive specimen for
- 396 COPD assessment. *Respiratory Research* 2022;23:16.
- 397 6. Budden KF, Shukla SD, Rehman SF, Bowerman KL, Keely S, Hugenholtz P, Armstrong-James DPH,
- Adcock IM, Chotirmall SH, Chung KF, Hansbro PM. Functional effects of the microbiota in chronic
 respiratory disease. *The Lancet Respiratory Medicine* 2019;7:907–920.
- 400 7. Marsland BJ, Gollwitzer ES. Host–microorganism interactions in lung diseases. *Nat Rev Immunol*401 2014;14:827–835.
- 402 8. Ubags NDJ, Marsland BJ. Mechanistic insight into the function of the microbiome in lung
 403 diseases. *European Respiratory Journal* 2017;50:.
- 404 9. Rand IAD, Blaikley J, Booton R, Chaudhuri N, Gupta V, Khalid S, Mandal S, Martin J, Mills J, Navani
- 405 N, Rahman NM, Wrightson JM, Munavvar M, Group on behalf of the BTSBG. British Thoracic
- 406 Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. *Thorax*

407 2013;68:i1–i44.

- 408 10. Gaeckle NT, Pragman AA, Pendleton KM, Baldomero AK, Criner GJ. The Oral-Lung Axis: The
- 409 Impact of Oral Health on Lung Health. *Respir Care* 2020;65:1211–1220.
- 410 11. Mammen MJ, Scannapieco FA, Sethi S. Oral-lung microbiome interactions in lung diseases.
- 411 *Periodontology 2000* 2020;83:234–241.
- 412 12. Huffnagle GB, Dickson RP, Lukacs NW. The respiratory tract microbiome and lung inflammation:
- 413 a two-way street. *Mucosal Immunol* 2017;10:299–306.
- 414 13. Dyakova EY, Kapilevich LV, Shylko VG, Popov SV, Anfinogenova Y. Physical exercise associated
- 415 with NO production: signaling pathways and significance in health and disease. *Front Cell Dev*
- 416 *Biol* 2015;3:19.
- 417 14. Bescos R, Brookes ZLS, Belfield LA, Fernandez-Sanjurjo M, Casas-Agustench P. Modulation of oral

418 microbiota: A new frontier in exercise supplementation. *PharmaNutrition* 2020;14:100230.

- 419 15. Cutler C, Kiernan M, Willis JR, Gallardo-Alfaro L, Casas-Agustench P, White D, Hickson M,
- 420 Gabaldon T, Bescos R. Post-exercise hypotension and skeletal muscle oxygenation is regulated by
- 421 nitrate-reducing activity of oral bacteria. *Free Radical Biology and Medicine* 2019;143:252–259.
- 422 16. Pavitt MJ, Tanner RJ, Lewis A, Buttery S, Mehta B, Jefford H, Curtis KJ, Banya WAS, Husain S,
- 423 Satkunam K, Shrikrishna D, Man W, Polkey MI, Hopkinson NS. Oral nitrate supplementation to
- 424 enhance pulmonary rehabilitation in COPD: ON-EPIC a multicentre, double-blind, placebo-
- 425 controlled, randomised parallel group study. *Thorax* 2020;75:547–555.
- 426 17. Clauss M, Gérard P, Mosca A, Leclerc M. Interplay Between Exercise and Gut Microbiome in the

427 Context of Human Health and Performance. *Frontiers in Nutrition* 2021;8:.

- 428 18. Gammal AIE, O'Farrell R, O'Mahony L, Shanahan F, Killian K, O'Connor TM. Systemic
- 429 Inflammatory Markers and Disease Severity in Chronic Obstructive Pulmonary Disease—The
- 430 Effect of Acute Exercise and Pulmonary Rehabilitation. *Open Journal of Respiratory Diseases*
- 431 2015;5:19–31.
- 432 19. van der Vlist J, Janssen TWJ. The potential anti-inflammatory effect of exercise in chronic
- 433 obstructive pulmonary disease. *Respiration* 2010;79:160–174.

- 434 20. Gigliotti F, Coli C, Lombardelli L, Romagnoli I, Logiodice F, Lanini B, Kullolli O, Binazzi B, Parronchi
- 435 P, Maggi E, Piccinni M-P. Effect of pulmonary rehabilitation (PR) on inflammation status in

436 patients with COPD. *European Respiratory Journal* 2015;46:.

- 437 21. Melo-Dias S, Cabral, Miguel, Furtado, Andreia, Souto-Miranda, Sara, Mendes, Maria Aurora,
- 438 Cravo, João, Almeida, Catarina Rodrigues, Marques, Alda, Sousa, Ana A. The effect of pulmonary
- 439 rehabilitation in salivary microbiota of people with chronic obstructive pulmonary disease: A
- 440 longitudinal study. 2022;
- 441 22. Furtado, Andreia, Melo-Dias S, Cabral, Miguel, Marques A, Sousa A. The effect of pulmonary
- 442 rehabilitation in salivary microbiota of people with chronic obstructive pulmonary disease: A
- 443 longitudinal study. 2021;
- 444 23. Melo-Dias S, Cabral, Miguel, Furtado, Andreia, Souto-Miranda, Sara, Almeida, Catarina
- Rodrigues, Marques A, Sousa A. The Effectiveness of pulmonary rehabilitation in COPD is
 associated with specific shifts in oral microbiota. 2022;
- 447 24. Elm E von, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the
- 448 reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting
- 449 observational studies. *BMJ* 2007;335:806–808.
- 450 25. GOLD Global Strategy for Diagnosis, Management, and prevention of chronic obstructive
 451 pulmonary disease 2020 report. 2020. 1–141.
- 452 26. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European

453 Respiratory Society Technical Statement | American Journal of Respiratory and Critical Care

- 454 Medicine. at <https://www.atsjournals.org/doi/full/10.1164/rccm.201908-1590ST>.
- 455 27. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, McCormack MC, Carlin BW,
- 456 Sciurba FC, Pitta F, Wanger J, MacIntyre N, Kaminsky DA, Culver BH, Revill SM, Hernandes NA,
- 457 Andrianopoulos V, Camillo CA, Mitchell KE, Lee AL, Hill CJ, Singh SJ. An official European
- 458 Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic
- 459 respiratory disease. *European Respiratory Journal* 2014;44:1428–1446.

460	28.	Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N. Development and first
461		validation of the COPD Assessment Test. European Respiratory Journal 2009;34:648–654.
462	29.	Jones PW, Tabberer M, Chen W-H. Creating scenarios of the impact of COPD and their
463		relationship to COPD Assessment Test (CAT [™]) scores. <i>BMC Pulm Med</i> 2011;11:42.
464	30.	Marques A, Jácome C, Rebelo P, Paixão C, Oliveira A, Cruz J, Freitas C, Rua M, Loureiro H,
465		Peguinho C, Marques F, Simões A, Santos M, Martins P, André A, De Francesco S, Martins V,
466		Brooks D, Simão P. Improving access to community-based pulmonary rehabilitation: 3R protocol
467		for real-world settings with cost-benefit analysis. BMC Public Health 2019;19:676.
468	31.	Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically
469		important differences in pharmacological trials. Am J Respir Crit Care Med 2014;189:250–255.
470	32.	Holland AE, Hill CJ, Rasekaba T, Lee A, Naughton MT, McDonald CF. Updating the minimal
471		important difference for six-minute walk distance in patients with chronic obstructive pulmonary
472		disease. Arch Phys Med Rehabil 2010;91:221–225.
473	33.	Kon SSC, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, Haselden BM, Polkey MI, Man
474		WD-C. Minimum clinically important difference for the COPD Assessment Test: a prospective
475		analysis. Lancet Respir Med 2014;2:195–203.
476	34.	Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H, Alm EJ,
477		Arumugam M, Asnicar F, Bai Y, Bisanz JE, Bittinger K, Brejnrod A, Brislawn CJ, Brown CT, Callahan
478		BJ, Caraballo-Rodríguez AM, Chase J, Cope EK, Da Silva R, Diener C, Dorrestein PC, Douglas GM,
479		Durall DM, Duvallet C, Edwardson CF, Ernst M, Estaki M, et al. Reproducible, interactive, scalable
480		and extensible microbiome data science using QIIME 2. Nat Biotechnol 2019;37:852–857.
481	35.	QIIME 2. at <https: qiime2.org=""></https:> .
482	36.	Prism - GraphPad. at < https://www.graphpad.com/scientific-software/prism/>.
483	37.	R: The R Project for Statistical Computing. at < https://www.r-project.org/>.
484	38.	Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using Ime4. Journal
485		of Statistical Software 2015;67:1–48.


486 39. Bakdash JZ, Marusich LR. Repeated Measures Correlation. *Frontiers in Psychology* 2017;8:.

- 487 40. Ramsheh MY, Haldar K, Esteve-Codina A, Purser LF, Richardson M, Müller-Quernheim J, Greulich
- 488 T, Nowinski A, Barta I, Stendardo M, Boschetto P, Korzybski D, Prasse A, Parr DG, Hohlfeld JM,
- 489 Döme B, Welte T, Heath S, Gut I, Morrissey JA, Ziegler-Heitbrock L, Barer MR, Singh D, Brightling
- 490 CE. Lung microbiome composition and bronchial epithelial gene expression in patients with
- 491 COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic
- 492 analysis. *The Lancet Microbe* 2021;2:e300–e310.
- 493 41. Wu BG, Sulaiman I, Tsay J-CJ, Perez L, Franca B, Li Y, Wang J, Gonzalez AN, El-Ashmawy M,
- 494 Carpenito J, Olsen E, Sauthoff M, Yie K, Liu X, Shen N, Clemente JC, Kapoor B, Zangari T, Mezzano
- 495 V, Loomis C, Weiden MD, Koralov SB, D'Armiento J, Ahuja SK, Wu X-R, Weiser JN, Segal LN.
- 496 Episodic Aspiration with Oral Commensals Induces a MyD88-dependent, Pulmonary T-Helper Cell
- 497 Type 17 Response that Mitigates Susceptibility to Streptococcus pneumoniae. *Am J Respir Crit*
- 498 *Care Med* 2021;203:1099–1111.
- 499 42. Horn KJ, Schopper MA, Drigot ZG, Clark SE. Airway Prevotella promote TLR2-dependent
- 500 neutrophil activation and rapid clearance of Streptococcus pneumoniae from the lung. *Nat*
- 501 *Commun* 2022;13:3321.
- 43. Wang Z, Locantore N, Haldar K, Ramsheh MY, Beech AS, Ma W, Brown JR, Tal-Singer R, Barer MR,
- 503 Bafadhel M, Donaldson GC, Wedzicha JA, Singh D, Wilkinson TMA, Miller BE, Brightling CE.
- 504 Inflammatory Endotype–associated Airway Microbiome in Chronic Obstructive Pulmonary
- 505 Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis. Am J Respir Crit
- 506 *Care Med* 2021;203:1488–1502.
- 507 44. Blood Eosinophils and Pulmonary Rehabilitation in COPD PubMed. at
- 508 <https://pubmed.ncbi.nlm.nih.gov/34777651/>.
- 45. Celli BR, Wedzicha JA. Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. N
- 510 *Engl J Med* 2019;381:1257–1266.

- 46. Rothia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with
- 512 chronic lung disease | European Respiratory Society. at
- 513 https://erj.ersjournals.com/content/early/2021/09/16/13993003.01293-2021>.
- 47. Burleigh MC, Liddle L, Monaghan C, Muggeridge DJ, Sculthorpe N, Butcher JP, Henriquez FL, Allen
- 515 JD, Easton C. Salivary nitrite production is elevated in individuals with a higher abundance of oral
- 516 nitrate-reducing bacteria. *Free Radic Biol Med* 2018;120:80–88.

517


519 Figures





520

521 Figure 1. Pulmonary rehabilitation modulates the microbiota composition of people with COPD, but 522 does not affect alpha diversity. A) Global rate of change of beta diversity was estimated by subtraction 523 of baseline values at all timepoints. Blue and grey loess lines were fitted over the data points 524 representing beta-diversity relative to baseline along time in the intervention and control groups, 525 respectively. The blue and grey areas represent the 0.95 confidence intervals. (M0=immediately prior 526 PR; M1, M2, M3= 1,2,3 months after initiating PR; M4, M5=1 and 2 months after finishing PR). 527 Intervention and control group presented different microbiota dynamics over the 5-month follow-up 528 (LMER on Weighted Unifrac distance matrix, Group:Time-Point, p<0.001). The grey rectangle indicates 529 the time interval spanning PR. B) Principal coordinate analysis of Weighted Unifrac distance between 530 groups in each timepoint. (M0, M1, M2, M3, M4 and M5). Significant differences in microbiota 531 composition between groups were observed in M1 (PERMANOVA, F=2.27, p=0.038). Blue and grey 532 dots and ellipses represent intervention and control groups, respectively. The biplot represented in M1 show the top ASVs contributing for sample segregation (5608c3e6c9de9ceb79610e7786bd0ac4: 533 534 Veillonella, d0b698c7298bf04110a6d2f220879bfb: melaninogenica, Prevotella


535e27680d4009f98f30248d823bc17fb8e:Haemophilusparainfluenzae,536a5189f77a2cfeab3bc1602ff5c8ac3e9: Streptococcus).C) No pre-post differences were observed in537alpha diversity (Phylogenetic index and Shannon diversity index) in the Intervention group (Wilcoxon538test: phylogenetic diversity: W= -85. p=0.48; Shannon diversity index: W=-1 p>0.99). *p<0.05,</td>539**p<0.01, ***p<0.001</td>







549 Figure 3. Responders and non-responders present distinct microbiota profiles prior to pulmonary 550 rehabilitation. A) Mean frequency of phyla and genera of bacteria present in Responders (R) and non-551 responders (NR) to dyspnoea, exercise capacity and impact of the disease. B) R and NR to dyspnoea 552 showed distinct microbiota composition prior to PR (PERMANOVA, p=0.04). PCoA analysis using 553 Emperor on Weighted UniFrac distance. The biplot (grey arrows) represent the 3 most relevant ASVs 554 for R and NR segregation. Prevotella melaninoaenica (ASV: d0b698c7298bf04110a6d2f220879bfb) was 555 the major contributor for segregation of R and NR followed by Veillonella dispar (ASV: 556 5608c3e6c9de9ceb79610e7786bd0ac) Haemophilus and parainfluenzae (ASV: 557 e27680d4009f98f30248d823bc17fb8e). In blue is represented the area where samples presented a 558 mean frequency of *P. melaninogenica* below the average of the dataset. 78% of R showed reduced 559 mean frequencies of *P. melaninogenica* prior to PR while only 37% of NR followed the same trend. C) 560 Cladogram highlighting differentially abundant genera between R and NR to dyspnoea prior to PR, 561 inferred by linear discriminant analysis (LEfSe) at a significance cut-off of 3. Prevotella is significantly enriched in NR to dyspnoea, with an effect-size of 9. 562



564 Figure 4. Responders and non-responders to dyspnoea, exercise capacity and impact of the disease 565 present distinct patterns of longitudinal bacteria-inflammatory markers' correlation. Correlation 566 networks representing the repeated-measures correlations between bacteria and inflammatory 567 markers in non-responders and responders to A) dyspnoea (rmcorr: [-0.75 - 0.52]) B) exercise capacity 568 (rmcorr: [-0.73 - 0.66]) and **C)** impact of the disease (rmcorr: [-0.72 - 0.63]). Prior to the analysis, genera and ASVs: d0b698c7298bf04110a6d2f220879bfb and a5189f77a2cfeab3bc1602ff5c8ac3e9 569 570 relative frequencies were transformed with arcsine square root transformation and inflammatory 571 markers' concentration was transformed with log₁₀. The diameter of the nodes is proportional to the number of connections. Bacterial nodes are coloured with the colour code of each bacterial phyla 572 573 (Firmicutes: yellow, Bacteroidetes: blue; Proteobacteria: red; Fusobacteria: green Actinobacteria: pink; 574 Other phyla: grey). Inflammatory markers' nodes are represented in beige. Positive correlations are 575 represented in red, while negative correlations are represented in blue. The width of edges is 576 proportional to the correlation coefficient.




Figure 5. Responders and non-responders to dyspnoea, exercise capacity and impact of the disease 578 present distinct patterns of longitudinal bacteria-bacteria correlation. Correlation networks 579 580 representing the longitudinal correlations between a subset of bacterial genera and ASVs: 581 d0b698c7298bf04110a6d2f220879bfb and a5189f77a2cfeab3bc1602ff5c8ac3e9 non-responders and responders to A) dyspnoea (rmcorr: [-0.6 - 0.9]), B) exercise capacity (rmcorr: [-0.73 - 0.46]), and C) 582

impact of the disease (rmcorr: [-0.71 – 0.44]). Grey triangles highlight common patterns of bacterial correlations between domains. Empty blue and red circles represent cytokines with which the correspondent taxon negatively and positively correlates, respectively. These correlations were inferred through the correlation analysis between bacteria-inflammatory markers and are represented here to facilitate the interpretation of the bacteria-bacteria correlation network.

588 Prior to the analysis, genera ASVs: d0b698c7298bf04110a6d2f220879bfb and and 589 a5189f77a2cfeab3bc1602ff5c8ac3e9 relative frequencies were transformed with arcsine square root transformation. The diameter of the nodes is proportional to the number of connections. Bacterial 590 591 nodes were coloured according to the colour code of each bacterial phyla (Firmicutes: yellow, 592 Bacteroidetes: blue; Proteobacteria: red; Fusobacteria: green Actinobacteria: pink; Other phyla: grey). 593 Positive correlations were represented in red, while negative correlations were represented in blue. 594 The width of edges is proportional to the correlation coefficient.

Tables 596

Table 1 – Sociodemographic, anthropometric, and clinical characteristics of individuals with 597

chronic obstructive pulmonary disease at beginning of the study (n=76). 598

Characteristics	Intervention group (n=38)	Control group (n=38)	<i>p</i> -value
Age (years), mean±SD	72±9	70±7.60	0.19 ¹
Gender, n (%)			0.57 ²
Male	29 (76%)	31 (82%)	
Female	9 (24%)	7 (18%)	
BMI (kg/m²), mean±SD	26±4	26.4±4.8	0.72 ³
FEV _{1PP} , mean±SD	49.2±16.0	52.3±19.8	0.53 ¹
FVC _{PP} , mean±SD	77.8±17.3	76.9±27.9	0.68 ¹
Pack-years, mean±SD	42.4±43.0	53.0±51.2	0.27 ¹
Comorbidities (CCI), mean±SD	4.2±1.4	3.8±1.3	0.10 ¹
GOLD grade, n (%)			0.224
1	3 (8%)	6 (16%)	
2	14 (37%)	12 (32%)	
3	20 (53%)	15 (39%)	
4	1 (3%)	5 (13%)	
GOLD group, n (%)			0.069 ⁴
Α	8 (21%)	17 (45%)	
В	20 (53%)	12 (32%)	
С	0 (0%)	1 (3%)	
D	10 (26%)	8 (21%)	
Medication, n (%)			
ICS	21 (55%)	19 (50%)	0.84
LABA	33 (87%)	30 (79%)	0.364
LAMA	24 (63%)	25 (66%)	>0.99
LTRA	2 (5%)	2 (5%)	>0.994
SABA	9 (24%)	5 (13%)	0.37 ⁴
SAMA	2 (5%)	0 (5%)	0.49 ⁴
Macrolides in stability	0 (0%)	0 (0%)	>0.99
Number of exacerbations in the last year, n (%)			0.60 ²
0 or 1	27 (71%)	29 (76%)	
≥2 or 1 with a hospitalisation	11 (29%)	9 (24%)	
Number of hospitalisations in the last year due to COPD, n (%)			0.674
0	32 (84%)	34 (89%)	
1	2 (5%)	3 (8%)	
2	3 (8%)	1 (3%)	
Missing values	1 (3%)	0 (0%)	
mBORG, mean±SD	0.8±1.3	0.5±1.0	0.3 ¹
CAT, mean±SD	17.1±8.1	11.7±7.4	0.003 ¹
Walked distance in 6MWT, mean±SD	389.0±133.9	457.5±82.8	0.045 ¹

SD: standard deviation, n (%): absolute and relative frequency, respectively; BMI: body mass index, FEV_{1pp}: forced expiratory volume in 1 second percent predicted, CCI: charlson comorbidity index, GOLD: global initiative for chronic obstructive lung disease, ICS: inhaled corticosteroids, LABA: longacting beta agonists, LAMA: long-acting muscarinic agonists, LTRA: leukotriene receptor antagonists, SABA: short-acting beta agonists, SAMA: short-acting muscarinic agonists, ¹ p-value obtained with Mann Whitney U-test, ² p-value obtained with Chi-square test, ³ p-value obtained with unpaired ttest with Welch's correction, ⁴ p-value obtained with Fisher's exact test.

599

=

600 Table 2 - Summary table of significant linear mixed effect models established to assess

601 differences in microbiota dynamics between intervention and control groups.

OTUs/ASVs longitudinal dynamics		<i>p</i> -value (TP:Group)
Fusobacteria	5.86	0.016
Atopobium	5.51	0.019
Streptococcus	5.03	0.026
Dialister	6.39	0.012
Parvimonas	4.75	0.030
Fusobacterium	7.00	0.009
a5189f77a2cfeab3bc1602ff5c8ac3e9: Streptococcus	4.96	0.027
d0b698c7298bf04110a6d2f220879bfb: Prevotella melaninogenica	4.34	0.038
e27680d4009f98f30248d823bc17fb8e: Haemophilus parainfluenzae	0.18	0.673
5608c3e6c9de9ceb79610e7786bd0ac4: Veillonella	3.30	0.070

Models were produced based on the longitudinal relative frequencies of phyla, genera, and ASVsa5189f77a2cfeab3bc1602ff5c8ac3e9,d0b698c7298bf04110a6d2f220879bfb,e27680d4009f98f30248d823bc17fb8e and 5608c3e6c9de9ceb79610e7786bd0ac4. Data upon relativefrequencies was transformed with arcsine and square root transformation. TP: time-point

- 603 Table 3 Summary table of significant linear mixed effect models established to assess
- 604 differences in microbiota dynamics between responders and non-responders to dyspnoea,
- 605 exercise capacity and impact of the disease.

OTUs/ASVs longitudinal dynamics	test's statistics	<i>p</i> -value (TP:Group)
Response to dyspnoea during exercise (Borg Modified Scale of Dyspnoea) MCID: -1 point		
Spirochaetes	2.33	0.046
TM7	5.40	0.000
Oribacterium	2.68	0.024
Dialister	2.69	0.023

⁶⁰²

Schwartzia	2.55	0.036
[Mogibacteriaceae]	2.45	0.036
Bulleidia	3.08	0.011
Treponema	2.33	0.046
Response to exercise capacity (6-minute walk test) MCID: +25m		
Lautropia	2.87	0.017
Response to impact of the disease (COPD assessment test) MCID: -2 points		
d0b698c7298bf04110a6d2f220879bfb: Prevotella melaninogenica	2.58	0.029

Models were produced based on the longitudinal relative frequencies of phyla, genera, a5189f77a2cfeab3bc1602ff5c8ac3e9 and d0b698c7298bf04110a6d2f220879bfb. Data upon relative frequencies was transformed with arcsine and square root transformation. TP: time-point

606